Skip to main content

It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)
Contact +33 (0)3 90 20 54 70

📢 ProteoGenix Loyalty Program is live — Earn points on every online order. Discover the program

🚀 Special Offer🚀Get 25% off on your bioreagent online order (except Micelles and Nanodiscs), with the code: PROTEOSHOP25

📢 New ! Accelerate your Antibody Development with Ready-to-use Stable Cell Pools

Explore Now
Brand: ProteoGenix

Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific Antibody (Research Grade)

Isotype:
(scFv-kappa-heavy)-(scFv-heavy-kappa); His-Tag

€200.00

+ 200 loyalty points
Size
Clear
  • In Stock
  • Free shipping in EU on orders > €500
  • Wide range of unique reagents
  • Fast worldwide delivery
SDS-PAGE for Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade

Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific Antibody (Research Grade)

Product name Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade
Source CAS 853426-35-4
Species Mus musculus
Molecular weight 54.1kDa
Purity >85%
Buffer PBS buffer PH7.5
Delivery condition Blue ice (+4°C)
Delivery Time 3-5 days if in stock; 3-5 weeks if production needed
Storage condition store at -80°C
Brand ProteoGenix
Applications ELISA,WB
Aliases /Synonyms Blinatumomab,AMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3,CD19, CD3E,anti-CD19, CD3E
Reference PX-TA1067
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype (scFv-kappa-heavy)-(scFv-heavy-kappa); His-Tag
Clonality Monoclonal Antibody
Product name Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade
Source CAS 853426-35-4
Species Mus musculus
Expression system Mammalian cells
Molecular weight 54.1kDa
Purity >85%
Buffer PBS buffer PH7.5
Delivery condition Blue ice (+4°C)
Delivery Time 3-5 days if in stock; 3-5 weeks if production needed
Storage condition store at -80°C
Brand ProteoGenix
Applications ELISA,WB,,,
Aliases /Synonyms Blinatumomab,AMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3,CD19, CD3E,anti-CD19, CD3E
Reference PX-TA1067
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype (scFv-kappa-heavy)-(scFv-heavy-kappa); His-Tag
Clonality Monoclonal Antibody

Blinatumomab biosimilar is a recombinant bispecific antibody targeting CD19 and CD3E, developed for research applications in immuno-oncology and T-cell engager studies. This research-grade antibody reproduces the mechanism of action of Blinatumomab by redirecting cytotoxic T cells toward CD19-expressing B cells.

Produced under strict quality control, this recombinant antibody is suitable for a wide range of immunotherapy, leukemia, and lymphoma research studies.

ProteoGenix provides high-quality research antibodies at competitive pricing, enabling laboratories to access reliable reagents for advanced immunology and oncology research.

Pricing and Availability

This Blinatumomab biosimilar antibody is available for research use with flexible purchasing options depending on quantity and project requirements.

Product Highlights

  • Recombinant Blinatumomab biosimilar
  • Targets CD19 and CD3E
  • Bispecific T-cell engager antibody
  • High purity research-grade material
  • Competitive price for research laboratories
  • Suitable for immuno-oncology studies

Applications

This antibody can be used in:

  • Immuno-oncology research
  • T-cell engager assays
  • Cytotoxicity studies
  • Flow cytometry experiments
  • Functional immune assays
  • Leukemia and lymphoma research

SDS-PAGE for Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade

SDS-PAGE for Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade

Blinatumomab Biosimilar - Anti-CD19, CD3E mAb - Research Grade on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue.. The purity of the antibody is greater than 95%.

  • Park AK, Monroy I, Ren Y, Lu C, Chaurasiya S, Valencia H, et al. Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors. Journal for ImmunoTherapy of Cancer. 2025;13:e011051. https://doi.org/10.1136/jitc-2024-011051

There are no reviews yet.

Be the first to review “Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific Antibody (Research Grade)”

Your email address will not be published. Required fields are marked *

Related products

Recently viewed products

Loading recently viewed products…

Can’t find what you need?

Our catalog doesn’t cover everything — but our team does. Whether you need a custom antibody, a specific protein variant, or a bulk order, our scientists are here to help.

Contact Our Team Book a Call

Cart (0 Items)

Your cart is currently empty.

View Products